<DOC>
	<DOCNO>NCT00030849</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Interferon alfa may interfere growth cancer cell . Combining chemotherapy interferon alfa may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine bexarotene interferon alfa treat patient cutaneous T-cell lymphoma .</brief_summary>
	<brief_title>Bexarotene Interferon Alfa Treating Patients With Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate response duration patient cutaneous T-cell lymphoma treat bexarotene , absence complete response , interferon alfa . - Determine safety toxicity patient treated regimen . OUTLINE : This multicenter study . Patients receive oral bexarotene daily 8 week . Patients complete response ( CR ) 8 week continue bexarotene alone least another 8 week absence unacceptable toxicity . Patients progress relapse bexarotene therapy achieve less CR 8 week begin receive interferon alfa subcutaneously 3 time week oral bexarotene daily least another 8 week absence continue disease progression unacceptable toxicity . Patients follow 4 week . PROJECTED ACCRUAL : A total 20-45 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cutaneous Tcell lymphoma Stage IB , IIA , IIB , III , IV Measurable assessable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Hemoglobin least 9 g/dL WBC least 1,500/mm^3 Platelet count least 70,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 3 time upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN Fasting triglyceride normal ( normalization antilipemic agent allow prior study ) No severe decompensated liver disease ( e.g. , cirrhosis , autoimmune hepatitis , significant liver dysfunction ) Renal : Calcium great 11.5 mg/dL Creatinine great 2 time ULN Cardiovascular : No myocardial infarction past 6 month No unstable angina No class III IV congestive heart failure No ventricular tachyarrhythmias Pulmonary : No pulmonary infiltrates clinical pulmonary impairment Other : HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use 2 form effective contraception 1 month , , 1 month study therapy No known allergy sensitivity interferon alfa bexarotene component study drug No uncontrolled thyroid disorder No concurrent serious medical illness would preclude study No infection No history pancreatitis No history neuropsychiatric disorder require hospitalization No history autoimmune disease would pose significant risk Must willing able avoid prolong exposure sun ultraviolet light PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent systemic anticancer chemotherapy Endocrine therapy : No concurrent systemic corticosteroid Radiotherapy : No concurrent localize radiotherapy target lesion unless consider show progressive disease Surgery : Not specify Other : At least 30 day since prior systemic dos 15,000 IU per day vitamin A retinoid class drug At least 30 day since prior participation investigational drug study No concurrent systemic antipsoriatic drug therapies No concurrent systemic anticancer drug therapies No concurrent gemfibrozil No concurrent investigational medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>